Compare Quest Diagnostics Inc (DGX) vs Micron Technology, Inc. (MU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Micron Technology, Inc. — how do they compare? Quest Diagnostics Inc trades at $205.37 (market cap $22.80B), while Micron Technology, Inc. trades at $976.39 (market cap $1.11T). The key difference: Micron Technology, Inc. is far larger — about 48.7× Quest Diagnostics Inc's market cap, and Quest Diagnostics Inc pays the higher dividend (1.67%). Which is the better fit depends on your goals.
| DGX | MU | |
|---|---|---|
Market Cap | $22.80B | $1.11T |
Sector | Health | Technology |
52-Week High | $216.02 | $1.21K |
52-Week Low | $166.42 | $104.88 |
Enterprise Value | $28.82B | $1.09T |
Dividend Yield | 1.67% | 0.05% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $207.35, showing minimal daily movement with a slight decline of 0.04%. The stock maintains a bullish technical stance with recent earnings beats and analyst consensus pointing to upside potential. Recent developments include New York State approval for Haystack MRD testing and strong momentum across diagnostic channels. Revenue growth accelerated to $11.04 billion in 2025 with consistent profitability margins around 9%.
DGX presents a balanced investment case with 38% analyst buy ratings and a $227.75 price target suggesting 10% upside. The company demonstrates steady revenue growth and operational efficiency, though elevated debt levels and policy risks require monitoring. Second quarter earnings on July 23, 2026, will be crucial for validating current momentum and growth trajectory.
Micron Technology (MU) trades at $937.00, down 4.32% today, but maintains strong bullish technical momentum with support near $924. The company demonstrates robust fundamentals, with Q1 2026 EPS beating estimates at $25.11 versus $20.98 expected, and revenue growth accelerating to $37.38 billion in 2025. Analyst sentiment remains overwhelmingly positive, with 81% recommending Buy and a consensus price target of $1,550.
Outlook is favorable driven by AI memory demand and pricing power, though risks include competitive pressure from SK Hynix and cyclical semiconductor volatility. Cash flow trends show strengthening operational performance, with net cash flow turning positive at $2.59 billion in 2025, supporting future growth investments and shareholder returns via dividends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Micron Technology, Inc.
Micron historically focused on designing and manufacturing DRAM for PCs. The firm then expanded into the NAND flash memory market. It increased its DRAM scale with the purchase of Elpida (completed in mid-2013) and Inotera (completed in December 2016). The firm's DRAM and NAND products tailored to PCs, data centers, smartphones, game consoles, automotives, and other computing devices.
Read more on MU →
